# US 2015/0177243 A1 · METHODS AND COMPOUNDS FOR DIAGNOSING THREONYL-tRNA SYNTHETASE-ASSOCIATED DISEASES AND CONDITIONS

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0177243 A1
- Document ID: US20150177243A1
- Status: Published application
- Kind: A1
- Application number: 14/416,347
- Filed: 2013-07-24
- Published: 2015-06-25
- Earliest claimed: 2012-07-25
- Assignees: Uiversity of Vermont and State Agricultural College
- Applicants: University of Vermont and State Agricultural College
- Inventors: Christopher Francklyn; Karen M. Lounsbury; Tamara Williams
- Web page: https://patentgrep.com/patent/US20150177243A1

## CPC

- G01N 33/573: for enzymes or isoenzymes
- C12Q 1/25: involving enzymes not classifiable in groups C12Q1/26 {- C12Q1/66}
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/57595: {involving intracellular compounds}
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/158: Expression markers
- G01N 2333/9015: Ligases (6)
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N 2800/7014: (Neo)vascularisation - Angiogenesis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The invention includes, in part, methods and compounds for diagnosing diseases and conditions characterized by altered threonyl-tRNA synthetase (TARS) activity, which include, but are not limited to diseases and conditions in which angiogenesis is altered. In some embodiments of the invention, a level of a TARS molecule is determined and compared to a control level of TARS to assess onset, progression, and/or regression of a disease or condition associated with altered TARS activity.

## Claims

### Claim 1

A method of diagnosing a subject as having, or at increased risk of developing, a disorder associated with increased threonyl-tRNA synthetase (TARS) activity, the method comprising
(a) obtaining a biological sample from a subject;
(b) measuring the amount of a TARS molecule in the biological sample; and
(c) comparing the level of the TARS molecule in the biological sample to a normal control level of the TARS molecule, wherein a significant increase in the level of the TARS molecule in the subject biological sample compared to the normal control level is an indication that the subject has or is at increased risk of developing the disorder associated with increased TARS activity.

### Claim 2 (depends on 1)

The method of claim 1, wherein a significant increase in the level of the TARS molecule in the subject sample compared to the control determines that the subject is at increased risk of developing a disorder associated with increased TARS activity.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The method of claim 1 wherein the level of the TARS molecule is measured by measuring a secreted TARS molecule.

### Claim 5 (depends on 1)

The method of claim 1, wherein the level of the TARS molecule is measured by measuring a non-secreted TARS molecule.

### Claim 6 (depends on 1)

The method of claim 1, wherein the level of the TARS molecule is measured by measuring the activity of the TARS molecule.

### Claim 7 (depends on 1)

The method of claim 1, wherein the disorder associated with increased TARS activity is an angiogenesis-associated disorder.

### Claim 8 (depends on 7)

The method of claim 7, wherein the angiogenesis-associated disorder is a cancer, a tumor, a hemangioma, vascular overgrowth, venous malformation, arterial malformation, overweight, macular degeneration, inflammatory disease, psoriasis, diabetes, or rheumatoid arthritis.

### Claim 9

(canceled)

### Claim 10 (depends on 8)

The method of claim 8, wherein the cancer is a metastatic cancer.

### Claim at position 11

11-12. (canceled)

### Claim 13 (depends on 1)

The method of claim 1, wherein the TARS molecule comprises a TARS polypeptide.

### Claim 14

(canceled)

### Claim 15 (depends on 1)

The method of claim 1, wherein a means of the measuring comprises an immunological assay, nucleic acid determination, mass spectrometry, TARS aminoacylation assay, TARS active site determination assay, or a TARS binding assay comprising a TARS-binding reporter molecule.

### Claim 16

(canceled)

### Claim 17 (depends on 1)

The method of claim 1, further comprising selecting a treatment regimen for the subject based at least in part on the comparison of the level of the TARS molecule in the biological sample to the normal control level of the TARS molecule.

### Claim at position 17

18-22. (canceled)

### Claim 23

A method for determining a prognosis in a subject diagnosed with a disorder associated with increased threonyl-tRNA synthetase (TARS) activity, the method comprising:
(a) obtaining a biological sample from the subject;
(b) measuring a TARS molecule level in the subject's biological sample;
(c) comparing the TARS molecule level of the subject's sample with a control level of the TARS molecule; and
(d) correlating levels of the TARS molecule greater than the control level with an indication of unfavorable prognosis and levels of the TARS molecule at or below the control level with a favorable prognosis.

### Claim 24 (depends on 23)

The method of claim 23, wherein the disorder associated with increased TARS activity is an angiogenesis-associated disorder.

### Claim 25 (depends on 24)

The method of claim 24, wherein the angiogenesis-associated disorder is a cancer, a tumor, a hemangioma, vascular overgrowth, venous malformation, arterial malformation, overweight, macular degeneration, inflammatory disease, psoriasis, diabetes, or rheumatoid arthritis.

### Claim 26

(canceled)

### Claim 27 (depends on 25)

The method of claim 25, wherein the cancer is a metastatic cancer.

### Claim at position 23

28-29. (canceled)

### Claim 30 (depends on 23)

The method of claim 23, wherein a means of the measuring comprises an immunological assay, nucleotide determination (mRNA or DNA), mass spectrometry, TARS aminoacylation assay, TARS active site determination assay, or a TARS binding assay comprising a TARS-binding reporter molecule, or an ELISA assay.

### Claim 31 (depends on 23)

The method of claim 23, further comprising selecting a treatment regimen for the subject based at least in part on the determined prognosis.

### Claim at position 26

32-36. (canceled)

### Claim 37

A method for determining the metastatic potential of a cancer, the method comprising
(a) obtaining a biological sample from a subject having a cancer;
(b) measuring a level of a threonyl-tRNA synthetase (TARS) molecule in the biological sample; and
(c) comparing the level of the TARS molecule in the biological sample to a control level of the TARS molecule, wherein a significantly higher level of the TARS molecule in the sample compared to the control level of the TARS molecule indicates a higher metastatic potential for the cancer.

### Claim at position 28

38-40. (canceled)

### Claim 41 (depends on 37)

The method of claim 37, wherein a means for the measuring comprises an immunological assay, nucleotide determination (mRNA or DNA), mass spectrometry, TARS aminoacylation assay, TARS active site determination assay, a TARS binding assay comprising a TARS-binding reporter molecule, or an ELISA assay.

### Claim 42 (depends on 37)

The method of claim 37, further comprising selecting a treatment regimen for the subject based at least in part on the determined metastatic potential.

### Claim at position 31

43-53. (canceled)
